Join
Live feed
·
NEWSReleasevia Quantisnow
Protagonist Therapeutics Inc. logo

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

ByQuantisnow·Wall Street's wire, on your screen.
PTGX· Protagonist Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTGX (Protagonist Therapeutics Inc.) and more on Quantisnow.